Company Financial Calendar
| Event |
Date |
| Half year end |
30th June |
| Interim results announced |
August |
| Financial year end |
31st December |
| AGM |
Sept, 13, 2010 |
Company Financial Reports
Interim Financial Statements June 30, 2010
Annual Report 2009
Interim Financial Statements June 30, 2009
Annual Report 2008
Interim Financial Statements June 30, 2008
Annual Report 2007
Medgenics Admission Document December 2007
Regulatory Disclosures, Announcements and Notifications
Sep 1, 2010: Notice of Annual Meeting to be held September 13, 2010
Aug 16, 2010: Interim Results – Half Yearly Report for the six month period ended June 30, 2010
Aug 12, 2010: Medgenics Announces Issue of Equity for Consultancy Services
Jul 19, 2010: New Results in Phase I/II Trials to Treat Anemia
Jul 09, 2010: Directors Dealing and Block List
Jul 05, 2010: Statement Regarding Share Price Discrepancy
Jun 22, 2010: Higher Dose EPO Biopumps Working in Patients
Jun 09, 2010: Medgenics Enhances Strategic Advisory Board
Jun 07, 2010: Share Price Movement: significant share price movement & press coverage in both the MEDU & MEDG quotes
Jun 07, 2010: Directors Dealing and Block Listing interim review
May 26, 2010: Medgenics Successfully Closes Additional Financing Round
May 17, 2010: Appointment of Nomura-Code as Joint-Broker
May 05, 2010: Final Results: Medgenics announces its final results for the 12 months ended 31 Dec 2009
Apr 27, 2010: Medgenics Granted Approval for Extension of Anaemia Trial to Major New Medical Centre
Apr 15, 2010: Showcase at Major European Liver Meeting
Apr 14, 2010: Name Change of Nominated Advisor
Mar 05, 2010: Medgenics Successfully Closes Additional Financing Round
Feb 08, 2010: The directors entered into an agreement to purchase 192,591 common shares of US$ 0.0001 each
Feb 08, 2010: Board resolution was passed to issue and allot 1,275,000 common US $0.0001 shares in the Company
Jan 27, 2010: New Patent Approval Boosts Intellectual Property Portfolio at Medgenics
Dec 07, 2009: World Expert on Liver Disease Joins the Scientific Advisory Board of Medgenics
Dec 04, 2009: Block Listing Interim Review
Nov 04, 2009: Announcing the death of Lord Leonard Steinberg, Non-Executive Director
Nov 02, 2009: Mr. Joel Kanter acquired in the market 25,000 common shares
Oct 26, 2009: Lord Leonard Steinberg acquired in the market 25,000 common shares
Oct 23, 2009: Medgenics Signs development agreement with major international pharma company
Oct 07, 2009: Issue of Equity
Sep 30, 2009: Interim Results - Half Yearly Report for the six month period ended June 30 2009
Aug 27, 2009: Patient Nearing Unprecedented 11 months of Anemia Relief in Clinical Trial
Aug 20, 2009: New Medgenics Closing Brings Ongoing Fund Raising To $520,000
Jun 22, 2009: Medgenics closes first series of fund raising
Jun 16, 2009: Resolutions Adopted by Shareholders
Jun 04, 2009: The total number of Common Shares in issue
Apr 01, 2009: Non payment of warrant exercise
May 22, 2009: Preliminary Results: Medgenics announces its preliminary results for the 12 months ended 31 Dec 2008.
May 11, 2009: Medgenics requests Stockholder Action in connection with fund raising
Mar 27, 2009: Encouraging results of the Company’s ongoing EPODURE Biopump Phase I/II Clinical Trial
Feb 16, 2009: Directors’ Dealings
Feb 5, 2009: Medgenics Warrant repricing extension
Feb 03, 2009: Clinical Trial Update
Feb 03, 2009: Directors Dealing
Dec 23, 2008: BioPump Protein Therapy Technology Approved for Patent in the USA
Dec 17, 2008: Medgenics warrant repricing announcement
Dec 4, 2008: Issue of Options to Director
Dec 4, 2008: Six monthly Block statement
Nov 12, 2008: 17% of Medgenics Common Shares Now Unrestricted Using New Ticker MEDU
Nov 3, 2008: Medgenics Preliminary Data: The landmark Phase I/II clinical trial of Medgenics’ EPODURE Biopump
Sep 24, 2008: Interim Results - Half Yearly Report for the six month period ended June 30 2008
Sep 23, 2008 Statement: Share Price Movement
Jul 30, 2008: Medgenics Granted Approval to Commence Its Phase I/II Clinical Study of EPODURE to treat Anemia
Jul 4, 2008: Response from ISRAEL’S Ministry of Health on its Phase I/II clincal Trial with EPODURE in Anemia
Jun 30, 2008: Notification of transactions of directors, persons discharging managerial responsibility or connected persons
June 30, 2008: Issue of Equity Total Voting Rights
June 19, 2008: Medgenics announces preliminary results for the year ended 31 December 2007
June 4, 2008: Block Listing Interim Review
May 7, 2008: Medgenics appoints vice president of Clinical Affairs
Apr 30, 2008: Total Voting Rights
Apr 22, 2008: Announcement re Issue of Equity
Apr 14, 2008: Research Update: Medgenics on target to start Phase I/II clinical trials with EPODURE protein therapy for anaemia mid-2008 as planned
Mar 18, 2008: Medgenics consolidates corporate and R&D operations into new office facility
Feb 1, 2008: Lord Steinberg Appointment
Dec 4, 2007: Medgenics Admission to Trading
Dec 4, 2007: Medgenics Block Admission and ISIN update
Preliminary Announcement of AIM Submission
|
|
